echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > THE DNA anti-spinase gene ERCC6L in 12 tumors.

    THE DNA anti-spinase gene ERCC6L in 12 tumors.

    • Last Update: 2020-09-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Tumor is a complex and highly heterogeneic disease, the pathogenesis is not completely clear.
    rapidly growing accumulation of big tumor data, such as genomic and transcriptional data, provides an excellent opportunity to identify new tumor-related genes and gain an in-depth understanding of the molecular mechanisms of tumor development.
    The Kong Qingpeng team at the Kunming Institute of Zoology of the Chinese Academy of Sciences found that the ERCC6L gene was consistently and significantly higher in 12 tumors by analyzing transcriptional data from 12 tumors from the TCGA database.
    the gene is a newly discovered DNA lysogene that is closely related to embryonic development, but the relationship with tumors has never been reported.
    researchers first found in in-body cell experiments that silence ERCC6L significantly inhibited the proliferation of breast cancer cells (MCF-7, MDA-MB-231) and kidney cancer cells (786-0), with cell cycles blocked in stage G0/G1.
    further analysis of ERCC6L knock-down cell transcription group data and verification experiments found that: ERCC6L knock-down can significantly inhibit the RAB31 gene transcription and translation levels, while reducing the MAPK pathway downstream of RAB31 phosphorylation level and CDK2 protein expression.
    in order to verify the results of in-body experiments, the team conducted a naked mouse tumor experiment, the results showed that silence ERCC6L can be inoculated on the seventh day after the tumor cells began to significantly inhibit tumor growth.
    Not only that, the expression level of ERCC6L is highly related to the tumor stage of the patient, and the high expression of ERCC6L can indicate the low survival rate of tumor patients, suggesting that ERCC6L is a good marker of tumor prognostication, but also a potential target for tumor treatment and drug development.
    the findings were recently published in the journal Oncotarget.
    Shaoyan, a member of the project team, and Yu Qin, a doctoral student, are co-authors of the article, and researcher Kong Qingpeng and associate researcher He Yong han are side-by-side correspondents of the article.
    project has been supported by the Ministry of Science and Technology '973' project, the National Natural Science Foundation of China and the Chinese Academy of Sciences and other research fund projects.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.